Down-regulation of MYH10 driven by chromosome 17p13.1 deletion promotes hepatocellular carcinoma metastasis through activation of the EGFR pathway.
Qian JinMin ChengXia XiaYuqing HanJing ZhangPengbo CaoGangqiao ZhouPublished in: Journal of cellular and molecular medicine (2021)
Somatic copy number alterations (CNAs) are a genomic hallmark of cancers. Among them, the chromosome 17p13.1 deletions are recurrent in hepatocellular carcinoma (HCC). Here, utilizing an integrative omics analysis, we screened out a novel tumour suppressor gene within 17p13.1, myosin heavy chain 10 (MYH10). We observed frequent deletions (~38%) and significant down-regulation of MYH10 in primary HCC tissues. Deletion or decreased expression of MYH10 was a potential indicator of poor outcomes in HCC patients. Knockdown of MYH10 significantly promotes HCC cell migration and invasion in vitro, and overexpression of MYH10 exhibits opposite effects. Further, inhibition of MYH10 markedly potentiates HCC metastasis in vivo. We preliminarily elucidated the mechanism by which loss of MYH10 promotes HCC metastasis by facilitating EGFR pathway activation. In conclusion, our study suggests that MYH10, a candidate target gene for 17p13 deletion, acts as a tumour suppressor and may serve as a potential prognostic indicator for HCC patients.
Keyphrases
- copy number
- hypertrophic cardiomyopathy
- mitochondrial dna
- end stage renal disease
- left ventricular
- newly diagnosed
- genome wide
- chronic kidney disease
- ejection fraction
- small cell lung cancer
- prognostic factors
- peritoneal dialysis
- dna methylation
- epidermal growth factor receptor
- tyrosine kinase
- binding protein
- patient reported
- metabolic syndrome
- transcription factor
- adipose tissue
- bone marrow
- patient reported outcomes
- mesenchymal stem cells
- type diabetes
- insulin resistance
- climate change
- genome wide identification